Bimekizumab-bkzx (Bimzelx) is the first dual interleukin 17A (IL-17A) and interleukin 17F (IL-17F) inhibitor to treat moderate-to-severe plaque psoriasis. It launches with a list price of $7200 per syringe.
Denise Myshko
Advertisement
Articles by Denise Myshko
As part of updates to its standard formulary, CVS Caremark has removed Amjevita and now prefers Hyrimoz and an unbranded biosimilar.
Advertisement
Latest Updated Articles
Specialty Therapies Offering Incremental Benefit Shouldn’t Be Added to Clinical Pathways, Hertler SaysPublished: October 11th 2021 | Updated:
Advertisement
Advertisement
Trending on AJMC
1
Leucovorin Treatment Expansion for Autism Symptoms Under FDA Review
2
US, Japan Patients With Diabetes Discontinue Semaglutide After First Year
3
How Clinician-Led Partnerships Strengthen Post-Acute Care
4
Contributor: Medication Adherence as a Journey—A Year-Round Strategy for Medicare Advantage Success
5
